In addition, and more importantly, initial [23], [56] and more recent [24] studies show the failure of either selective NK1 receptor antagonists or dual NK1/NK2 tachykinin receptor antagonist to afford protection in asthma. The gene discussed is TAC1; the disease is asthma.